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Abstract
Metabolomics time-course experiments pro-
vide the opportunity to understand the
changes to an organism by observing the
evolution of metabolic profiles in response
to internal or external stimuli. Along with
other omic longitudinal profiling technolo-
gies, these techniques have great potential
to complement the analysis of complex rela-
tions between variations across diverse omic
variables and provide unique insights into the
underlying biology of the system. However,
many statistical methods currently used to
analyse short time-series omic data are i)
prone to overfitting or ii) do not take into
account the experimental design or iii) do
not make full use of the multivariate infor-
mation intrinsic to the data or iv) unable to
uncover multiple associations between differ-
ent omic data. The model we propose is an
attempt to i) overcome overfitting by using a
weakly informative Bayesian model, ii) cap-
ture experimental design conditions through
a mixed-effects model, iii) model interdepen-
dencies between variables by augmenting the
mixed-effects model with a conditional auto-
regressive (CAR) component and iv) identify
potential associations between heterogeneous
omic variables by using a horseshoe prior.
Results: We assess the performance of our
model on synthetic and real datasets and
show that it outperforms existing models for
metabolomic longitudinal data analysis. Our
proposed method is able to identify metabolic
biomarkers related to treatment, infer per-
turbed pathways as a result of treatment and
find significant associations with additional
omic variables. We also show through sim-
ulation that an informative beta like prior
compares better than a non-informative uni-
form prior in inferring significant pathways.
On real data, we investigate how the number
of profiled metabolites can affect the predic-
tive ability of the model.
Supplementary material for this article are
available online.
1 INTRODUCTION
Over the past years, there has been a significant
development in high-throughput omics technologies
e.g. metabolomics, transcriptomics, genomics, epige-
nomics and proteomics along with a growing interest
into joint modelling of multi-omic data [11, 13]. In
metabolomics, several approaches are used to under-
stand the response of a biological system as a function
of an internal or external perturbation by monitoring
“the chemical fingerprints that specific cellular pro-
cesses leave behind” [9]. These chemical fingerprints
are most commonly interrogated in terms of metabo-
lite (i.e. low weight molecules) concentration, struc-
ture and transformation pathways (i.e set of chemi-
cal reactions) in order to identify a biomarker related
to the studied process. Biomarker discovery consists
of identifying a metabolite that has significant associ-
ation patterns with a particular phenotype (disease,
clinical variables, physical traits, etc) and that can
be thus used as an indicator of that specific pheno-
type. Typical experimental platforms use analytical
techniques such as nuclear magnetic resonance spec-
troscopy (NMR) [23] and mass spectrometry (MS) [10]
to generate appropriate spectral metabolomic profiles
of the studied biological system.
Metabolomic data sets are characterized by high cor-
relation structures in that many spectral peaks can
arise from the same metabolite and metabolites oper-
ate within networks of chemical reactions. In addition,
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further correlation structure is present in longitudinal
metabolomic studies due to repeated measurements of
observations over time. Additional challenges include
not only the low number of time points and samples
compared to the number of profiled metabolic vari-
ables, but also integration of a different omic data to
the metabolomic data.
First, metabolomic time series are often short due to
experimental costs or ethical considerations. Typi-
cally, less than 10 time points are available compared
to a large number of metabolic variables profiled at
each time point e.g. hundreds of metabolic variables
for targeted experiments and thousands of metabolic
variables for untargeted experiments. Taking into ac-
count the small number of time points compared to the
large number of metabolic variables profiled, the num-
ber of temporal patterns that will arise is limited (due
to the limited number of degrees of freedom). Some
temporal patterns will be repeated and thus these pat-
terns can be induced by randomness. Second, models
fitted to a small number of data points are often prone
to overfitting i.e. the model is very sensitive to small
fluctuations. This can lead to a poor fitting to unseen
data and a high generalisation error. Third, it is also
important to consider the number of parameters of the
statistical model and make use of the simplest models
in order to avoid overparametrisation. Finally, moni-
toring heterogeneous omic variables can substantially
enhance the understanding of the underlying biological
mechanism and provide a systems biology approach as
these omic variables represent entities that are often
involved in related cellular processes [11, 13].
For all these reasons, metabolomics scientists need
cautious estimates model parameters in order to en-
sure robust interpretation of the results. Hence, appro-
priate models are needed to integrate heterogeneous
omic data and take into account both experimental
conditions and biological variations in order to ex-
tract important information from the data. In this
paper, we are interested in dose-response time course
experiments where additional omic variables (bacte-
ria, genes, transcripts, etc) are monitored along with
metabolites in the context of biomarker discovery.
The main contribution of our work is a single proba-
bilistic generative model that i) can overcome overfit-
ting via the use of weakly informative priors ii) makes
use of mixed effects models to model the experimen-
tal design iii) models metabolite interactions by us-
ing pathway information through a conditional auto-
regressive (CAR) component and iv) uncovers multiple
associations between metabolites and other omic vari-
ables by using a horseshoe prior. An additional benefit
of our approach is that it naturally yields a list of per-
turbed metabolic pathways since it is based both on a
mixed effects component and a CAR component.
2 RELATED WORK
There is a growing interest in longitudinal experi-
ments for heterogeneous omics data and statistical
models to infer biomarkers of a particular treatment
or disease over time. Different approaches attempt
to infer influential or significant metabolites using dy-
namic metabolomic data under the assumption that
metabolites are independant. These models include
fitting smooth splines mixed effects models (SME) to
time curves [3] and linear mixed effects models aug-
mented with a variable selection approach [18] . How-
ever between-metabolite correlation is richly struc-
tured and biologically relevant and should be mod-
elled.
Seemingly unrelated regression accounts for metabo-
lite correlation by using correlated regression errors
and can be used to identify biologically significant
metabolites [6, 7]. In gene expression data analysis,
[21] recently proposed to use confirmatory factor anal-
ysis to capture gene-pathway relationship and a con-
ditional autoregressive model to capture relationships
between a set of pathways where pathway network has
been constructed based on KEGG [14] pathways. The
latter accounts for biological variation in the data and
allows ease of interpretation.
In the metabolomics literature, traditional frameworks
for metabolomic data analysis use dimensionality re-
duction techniques, namely principal component anal-
ysis (PCA), partial least squares (PLS) [27] and PLS
derived models (OPLS [26], O2PLS [25], OnPLS [17])
to take into account high correlation between metabo-
lites. Extension of PLS to O2PLS and OnPLS al-
lows for integrative analysis of heterogeneous omic
data. PCA and PLS models are very popular among
metabolomicists as tools for exploratory data analy-
sis, visualisation purposes and ease of interpretation.
One of the interests of PCA (PLS) derived models is
to be able to visually assess whether or not there is a
time effect in the data and identify metabolites that
change over time by looking into time trajectories of
each metabolite [antti2002].
Extensions to PCA (PLS) for longitudinal analysis in-
clude lagged PCA (PLS) and dynamic PCA (PLS)
where a backshift matrix is introduced to take into
account time dependancy. Similarly, [22] used a set
piecewise orthogonal projections latent structures to
describe changes between neighboring time points.
PARAFAC [4] is a multi-linear unsupervised decompo-
sition method that can account for the multi-way vari-
ation seen in dynamic metabolomics data. Recently,
dynamic probabilistic PCA (DPPCA) was proposed in
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[19] as a generative probabilistic model of longitudinal
metabolomic data where a stochastic volatility model
is used for the latent variables. The main inconve-
nience of these approaches is that further techniques
such as multiple testing correction have to be sepa-
rately applied to the data in order to identify biomark-
ers and they do not take heterogeneous data (i.e. data
from different omics techniques) into account.
In contrast, we here provide a single model that takes
into account metabolite interactions, time variation
and experimental design, infers influential metabolites
and also quantifies relationships between metabolites
and additional omic variables (if any).
3 MODEL FRAMEWORK
Given a metabolomics data X ∈ RN×T×M where
N is the number of observations, T the number of
time points and M the number of metabolites. Y ∈
RN×T×K is an additional continuous omic data mea-
sured along with X where K is the number of associ-
ated omic variables. The set of N observations consists
of a set of cases and controls. Throughout the paper,
index i always runs through observations, index t runs
through time points, index m runs through metabo-
lites and index k runs through Y variables. Vector
quantities are written in bold. Matrices are written
in bold capitals. Our goal is to build a simple model
that can identify biomarkers relative to a specific treat-
ment in time taking into account the multiple sources
of variations in the data.
The model is built on three levels: First, a CAR com-
ponent to capture interaction between metabolites.
Second, a variable selection model to uncover associa-
tions between metabolites and Y data. Third, a mixed
effects component to model experimental design. We
give more details about each level of our model respec-
tively in each of the following sections.
3.1 Metabolite interactions
In a similar fashion to [21], we model metabolite inter-
actions via the CAR model. In fact, incorporation of
pathway information in the CAR model through the
variance matrix helps provide chemists with an easily
interpretable model. First, we assume that the con-
centration of each metabolite is linearly influenced by
concentration levels of metabolites in the same path-
way. Let C ∈ RM×M be the design matrix quantify-
ing metabolite interactions such that matrix elements
cmm = 0, cmj 6= 0 if metabolites m and j are in the
same pathway and 0 otherwise. Thus, metabolite in-
tensity levels can be expressed as:
xitm|xit,−m,µit,C, σ ∼ N(µitm+
M∑
j=1
j 6=m
cmj(xitj−µitj), σ2)
(1)
where xit,−m represents measurements of metabolites
of sample i at time point t excluding metabolite m,
µitm is a function of covariates of sample i for metabo-
lite m at time point t. If we define IM the Mth order
identity matrix, the joint distribution of xit can be
explicitely written as [8]:
xit|µit,C, σ ∼ N
(
µit, (IM −C)−1 σ2
)
(2)
Chemists are most interested by identifying which
pathways are “on” or “off” as an effect of treatment.
In the CAR literature, the design matrix C can be
modeled as a scaled product of a diagonal weight ma-
trix and an adjacency matrix. In order to allow for
pathway perturbation inference we construct the dis-
tance matrix based on the individual contribution of
each pathway. To be precise, we define C (φ) =∑P
p=1 φpGpAp where P is the number of pathways.
The distance matrices Ap are a zero-diagonal sym-
metric adjacency matrices with elements apmj equal to
the inverse of the length of the shortest path between
metabolitesm and j if they are in pathway p and 0 oth-
erwise. A path between two metabolites consists in the
number of reactions that lead from one metabolite to
the other. The shortest path is the path that contains
the smallest number of reactions. In the diagonal ma-
trices Gp we use the reciprocal of the number of neigh-
bors of each metabolite in pathway p i.e (gpmm)
−1
=∑M
j=1(amj > 0) so that the squared partial correla-
tion cor
(
xitm, xitj |xit,−(m,j)
)2 ∝ φ2pgpmmgpjj is reduced
when more metabolites from the same pathway are
profiled [8]. The model parameter φ = {φp}Pp=1 is es-
timated. It quantifies pathway contribution and is re-
ferred to as spatial -dependence parameter in the CAR
literature.
The model needs to comply with the condition that
IM − C (φ) is positive definite. If we assume that
pathways are a priori equally perturbed, φp must fall
in the interval
(
1
Pξ1p
, 1Pξ2p
)
where ξ1p and ξ
2
p are the
minimum and maximum eigenvalues of GpAp, respec-
tively. In practice, strong interaction between ob-
served metabolites of pathway p is reproduced in CAR
models only when the scaling parameter φp is quite
close to one of the boundaries 1Pξ1p
, 1Pξ2p
. Hence, we
use a beta-type prior for φp that places substantial
mass on large values of |φp| [2] :
p (φp) =
1
B
(
1
2 ,
1
2
) (φp − 1
Pξ1p
)− 12 ( 1
Pξ2p
− φp
)− 12
(3)
Figure 1: Prior p (κmk|τ, σβm) on κmk for different
values of σβm and τ . The prior distribution skews
towards 1 if τ increases or σβm decreases.
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Figure 2: Left : Boxplots of Area Under the Curve
(AUC) for pathway perturbation inference with uni-
form prior on φ compared to a beta like prior on φ for
10 simulated datasets. We infer perturbations based
on the posterior distribution of φcontrols−φcases. Right
: Distribution of φcontrols − φcases under the uniform
prior (white) and the beta like prior (grey). True per-
turbed pathways are printed in bold on the x axis.
where B is the beta function. The parameter σ2 cap-
tures variance heterogeneity in metabolite intensities
and is given an inverse gamma prior G (ψ,ψ − 1). This
prior provides 2ψ pseudo-observations in addition to
NT available observations. In order to build a reason-
ably informative prior we set ψ = N × T/4.
3.2 Integrative analysis
Interactions between heterogeneous omic variables
such as transcripts and metabolites or gene expression
and metabolites is modeled via the following hierar-
chical shrinkage model:
µitm = αm + γim + yitβm + νitm (4)
βmk|λmk, σβm ∼ N
(
0, λ2mkσ
2
βm
)
(5)
λmk|τ ∼ St+ (τ, 0, 1) (6)
where St+ denotes the half Student-t distribution with
τ degrees of freedom, αm represents treatment effect
for metabolite m, γim ∼ N
(
0, σ2γm
)
represents indi-
vidual perturbations for metabolite m, νitm|νi,t−1,m ∼
N
(
θmνi,t−1,m, σ2νm
)
follows and auto-regressive pro-
cess and represents temporal effects for metabolite m
of individual i at time point t. Finally, βm quanti-
fies interactions between metabolite m and other omic
variables. λmk is called local shrinkage parameter
whilst σ2βm is the global shrinkage parameter. For
τ = 1, this prior reduces to the horseshoe prior. In-
tuitively, for small values of λmk the coefficient βmk is
very close to 0 while for relevant variables λmk will be
large. In addition, σβm controls the overall shrinkage
level i.e sparsity of the vector βm is more important
for small values of σβm .
Define κmk =
1
1 + λ2mkσ
2
βm
/τ
a random shrinkage co-
efficient such that κkm ≈ 0 when λmk is large and
κkm ≈ 1 when λmk is small. This transformation im-
plies the following prior distribution on κmk:
p (κmk|τ, σβm) =
1
2
√
piB
(
τ
2 ,
1
2
) στβmκτ/2−1mk (1− κmk)−1/2(
1− κmk + κmkσ2βm
)
(7)
This prior density is shown in figure 1 for different
values of σβm and τ . It reduces to a Beta(τ/2, 1/2)
distribution if σβm = 1 and to a Beta(1/2, 1/2) which
looks like a horseshoe, if in addition τ = 1. When
τ increases, Beta(τ/2, 1/2) skews towards 1 which in-
creases the global shrinkage power. The expectation
of βm given Y ,κm, τ,µtm can be expressed as:
E (βm|Y ,κm, τ,µtm) =
(
T∑
t=1
Y Tt Σ
−1
m Y t + τΥm
)−1
×
T∑
t=1
Y Tt Σ
−1
m µtm (8)
where Σm =
(
σ2νm
1−θ2m + σ
2
γm
)
IN and Υm is a diag-
onal matrix of order K with elements 1/κmk − 1.
Equation (8) introduces a penalty term τΥm where
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Figure 3: Average Receiver Operating Characteris-
tic (ROC) curves for pathway perturbation inference
across 10 datasets for different factions of “falsely” as-
signed metabolites.
Υm is a metabolite specific penalty term introduced
by the horseshoe prior and τ is a global penalty
term. Precisely, τ captures the overall sparsity level
amongst all metabolites. The expectation of βm given
Y ,κm, τ,µtm is very similar to the estimate of βm
under ridge regression where τΥm simply reduces to
τIN .
The global sparsity level can be controlled using τ .
Increasing the global sparsity level is a desired prop-
erty in omic studies, as usually we deal with a large
number of omic variables where only few are impor-
tant. Moreover, when there is prior knowledge avail-
able, specifying τ a priori can optimize the inference
and additionally, provide a more informative prior on
λmk. If we fix p
(
σ2βm
)
∝ 1/σ2βm , integrating over σβm
gives the expected value of κmk as :
E (κkm|τ) = Γ (1/2)
−1
2
√
piΓ (τ/2)
×G2,33,3
(
1, τ/2, 0
τ/2, τ/2− 1/2, 0
∣∣∣∣ 1− σ2βm)
where G·,··,· is Meijer’s G-function [meijer1936]. The
equation above can be used to fix τ a priori by defin-
ing the expected proportion of shrunk coefficients. In
practice, different values of τ are plugged into the
equation above to get the desired proportion of shrunk
coefficients. However, many definite integrals can be
obtained using the tables of Meijer functions in [5] for
special values of parameters.
3.3 Experimental design
The covariance structure between metabolites might
change drastically as a result of treatment if the lat-
ter affects metabolic pathways. The model can be
extended to take into account the experimental de-
sign. As specified in the previous section, αm cap-
tures the treatment effect for metabolite m, γim rep-
resents individual perturbations for metabolite m,
νitm|νi,t−1,m ∼ N
(
θmνi,t−1,m, σ2νm
)
represents tem-
poral effects for metabolite m of individual i at time
point t in equation (5). In addition, we allow covari-
ance structures C (φe) to be different for the control
samples and the cases where e ∈ {cases, controls} des-
ignates experimental groups. This yields the overall
hierarchical model:
xeit|µit,C, σ ∼ N
(
µit, (IM −C (φe))−1 σ2
)
(9)
µitm = αm + γim + yitβm + νitm (10)
βmk|λmk, σβm ∼ N
(
0, λ2mkσ
2
βm
)
(11)
λmk|τ ∼ St+ (τ, 0, 1) (12)
γim|σγm ∼ N
(
0, σ2γm
)
(13)
νitm|θm, σνm ∼ N
(
θmνi,t−1,m, σ2νm
)
(14)
Note that by specifying different dependence param-
eters for metabolite interactions in cases and controls
metabolism, the model is able to identify perturbed
pathways by comparing φcases and φcontrols.
4 RESULTS
In this section we perform experiments on both syn-
thetic and real data to investigate whether our al-
gorithm gives reasonable solutions. We first try our
method on a simulated dataset in section 4.1 to get
an understanding of the performance of our method.
In section 4.2, we test our method on a data set us-
ing metabolomic and bacterial composition in a drug
treatment experiment. In the following, we refer to
our model as “ iCARH ” model for “ integrative CAR
Horseshoe ” model.
4.1 Simulation study
To get better understanding of our method and test
its applicability, we first perform our approach on syn-
thetic datasets. We will mainly focus on the ability of
our model to infer pathway perturbation.
Assessing pathway inference with beta like
prior
In the first simulation our objective is to assess how
the beta like prior in equation (3) improves the iCARH
model. We first fixed the number of pathways P to 11,
then simulate the design matrices Ap. Specifically, a
membership matrix Z with dimensions M × P is ran-
domly generated based on the density of the number
of KEGG pathways in which a single metabolite is in-
volved. Each design matrix Ap is then equal to zpzp
T
where zp is the pth column of Z. Finally, we generated
10 datasets according to the model below in order to
assess how our model infers perturbed pathways:
ω ∼ Bernoulli (piω) (15)
φcontrolsp |ω ∼ ωN[0,1/Pξ2p]
(
1
Pξ2p
− ρ, σ2φ
)
+ (1− ω)N (0, ψ2) (16)
φcasesp |φcontrolsp , ω ∼ ωN[1/Pξ1p,0]
(
1
Pξ1p
+ ρ, σ2φ
)
+ (1− ω) δφcontrolsp (17)
with N[a,b] denotes the truncated normal distribution
with boundaries a, b, ξ1p and ξ
2
p are the minimum
and maximum eigenvalues of GpAp. The rest of the
parameters is set as follows : number of bacterial
variables K = 1, number of metabolites M = 40,
number of time points T = 7, number of samples
N = 22, global parameter τ fixed to 1.2, parame-
ters νitm, γim, µitm, x
e
it simulated according to equa-
tions (14), (13), (10), (9) respectively.
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Figure 4: Posterior predictive checks for mean absolute
deviation (MAD) compared to DPPCA for different
numbers of metabolites included. The MAD decreases
as the number of metabolites increases. Our model
performs clearly better than the DPPCA model.
We set non-informative uniform priors on αm, σγim ,
θm, σ
2
µm . We set an informative prior on σ
2
γm ∼
inverse-gamma (1, 0.1) as we expect low variability
amongst biological samples of the same group. We fix
piω to 0.7 the proportion of expected perturbed path-
ways. ρ is fixed to a value of 0.05, σ2φ to 0.2 and ψ to a
large value. We compare inference of the model under
a uniform prior for φep and the prior in equation (3).
Inference is done using 2000 iterations of Hamiltonian
Monte Carlo sampling and 1000 warm-up iterations.
The left plot in figure 2 shows the boxplots of the Area
Under the Curve (AUC) for pathway perturbation in-
ference for 10 simulated datasets with uniform prior
on φ and a beta like prior on φ. We infer perturba-
tions based on the posterior probability that φcontrols
and φcases are different i.e. the 95% credible inter-
val of φcontrols − φcases does not contain zero. The
AUC values for the beta like distribution is signifi-
cantly higher than the AUC values for the uniform
distribution. On average pathway peturbation infer-
ence under the uniform distribution reduces to a ran-
dom guess with an average AUC of 0.53. This is likely
due to the lack of variance of the uniform distribution.
The right plot in figure 2 shows the posterior distribu-
tions of φcases−φcases under the uniform prior (white)
and the beta like prior (grey) for each pathway. True
perturbed pathways are printed in bold on the x axis.
Assessing pathway inference against design
inaccuracies
It is very common in metabolomics data to find
metabolites that are correlated but not in the same
KEGG pathway. In the following simulation we as-
sess how inaccuracies in the covariance structure be-
tween metabolites and the design matrices Ap af-
fect the iCARH model. We used the 10 datasets
from the previous simulation and perturbed the design
matrices by selecting a random fraction of metabo-
lites in each pathway. We then randomly (falsely)
assign these metabolites to no pathway, or to dif-
ferent pathways. We similarly run the model for
2000 iterations of Hamiltonian Monte Carlo sampling
and 1000 warm-up iterations for each of the fractions
y = 0, 0.18, 0.35, 0.44, 0.5, 0.62 of perturbed metabo-
lites. Finally, in the same fashion, we assess perturba-
tions based on the 95% credible interval of φcontrols −
φcases. Figure 3 is a series of average Receiver Operat-
ing Characteristic (ROC) curves across 10 datasets for
each of the factions y. On average, the performance of
our model reduces to a random guess (AUC of 0.5) if
50% of the metabolites in each pathway is perturbed.
The AUC of our model reaches 0.97 if no metabolites
are perturbed and is about 0.88 if 18% of the metabo-
lites in each pathway are perturbed.
4.2 Case study
In this section, we test our model on an actual
metabolomic data and 16S data for bacterial profiles.
In this study we are interested in the influence of met-
formin on a non-diabetic model. Metformin is the first-
line medicine to treat type 2 diabetes. It has also been
Manuscript under review by AISTATS 2018
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Figure 5: Right and left panels show model fit as-
sessment for controls and cases data. Left : quantile-
quantile normal plot of Ψ−1cases (xit − µit). Right :
quantile-quantile normal plot of Ψ−1controls (xit − µit).
suggested that metformin has anti-cancer, cardiovas-
cular and anti-aging effects. Because of their very large
metabolic capacity, the gut bacteria can influence tox-
icity and metabolism of drugs. Here, we are partic-
ularly looking for metabolic biomarkers indicative of
microbiota changes as result of treatment.
The study design is as follows: metabolic profiles of
24 rats are acquired once a week using different mass
spectrometry techniques from plasma samples over a
period of 9 weeks. Bacterial profiles are acquired using
miSeq. The study has allowed for two groups of 12
rats where metformin has been administrated to the
second group (weeks 3 to 7) allowing for 2 weeks of
acclimatation (weeks 1 and 2) and 2 weeks of recovery
(weeks 8 and 9). After data processing and metabolite
identification, a total of 56 metabolites and 6 bacteria
species are further analysed using our model. Inference
is done using 2000 iterations of Hamiltonian Monte
Carlo sampling.
We assess performance of our model for different values
of τ using the Watanabe-Akaike information criterion
(WAIC). Tested values of τ comprise 1, 1.2, 5, 10 with
corresponding WAIC values of 7317.296 , 7322.798 ,
7317.457 , 7316.476 respectively. WAIC values are
very similar for different values of τ which suggests
to use the most selective model with τ = 10 as it is
the simplest i.e with the smallest number of selected
variables.
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Figure 6: Estimates of effects of treatment on metabo-
lite profiles are captured by βαm. Only part of the data
is plotted as we are only interested in “metabolite 27”.
Assessing model fit
In order to assess our model fit, we perform posterior
predictive checks of our model compared to DPPCA
[19]. The DPPCA model is a multivariate model using
PCA, where PCA scores are modeled via a stochastic
volatility model. In the Bayesian framework, posterior
predictive checks consist in comparing data simulated
from the posterior predictive distribution with the ob-
served data. We compared the simulated data and
the observed data by means of mean absolute devia-
tions (MADs) between the observed and the simulated
covariance matrices for different numbers of metabo-
lites included i.e only part of the data corresponding to
these metabolites is considered. The same process was
repeated for inference using the DPPCA model [19].
Figure 4 shows MADs of our model and the DPPCA
model. As expected, MADs for both models decrease
when the number of metabolites increases. Overall,
our model clearly outperforms the DPPCA model.
In addition to posterior predictive checks, goodness
of fit was also checked by using Ψ−1e (xit − µit) ∼
N (0, IM ) where Ψe denotes the Cholesky factor of
(IM −C (φe))−1 σ2. Zero-mean and normality were
thus checked for Ψ−1e (xit − µit) (See figure 5).
Data results
Since the administrated drug was also profiled us-
ing mass spectrometry, we fit the iCARH model with
αm = β
α
mydrug. Figure 6 is a series of boxplots for β
α
m
for metabolites 13 to 31. We are mainly interested in
“metabolite 27” as it is associated with some bacteria
species.
Figures 7 and 8 show posterior distributions of φe for
each pathway and estimates of effects of bacteria on
metabolites. Results in section 4.1 suggest to compare
the covariance structure of metabolites in the observed
data with the covariance induced by the design matri-
ces in order to have an a priori idea on the robust-
ness of pathway inference (See figure 3). For a corre-
lation threshold of 0.3, about 25% of the metabolites
are misspecified in the design matrices which corre-
sponds to an AUC around 0.8 according to figure 3.
If we set a higher correlation threshold, a lower num-
ber of metabolites will be misspecified. This supports
the use of the iCARH model for pathway perturbation
inference for this data.
Estimates of effects of bacteria on metabolite profiles
are captured by βm. Some metabolites present sig-
nificant changes along with the bacterial profiles. For
example, “metabolite 27”, a hydroxy fatty acid, is as-
sociated with alterations in abundance of 4 bacteria
species. Figure 7 shows that, as a result of treatment,
KEGG pathways are not significantly altered. How-
ever, distributions of φcontrols for “fatty acids biosyn-
thesis” and “biosynthesis of unsaturated fatty acids”
KEGG pathways are remarkably flatter than the dis-
tributions of φcases. These pathways involve the pre-
viously identified hydroxy fatty acid metabolite. Our
analysis confirms previously reported studies that hy-
droxy fatty acids might be produced by the gut micro-
biome [kishino2013, kimura2013].
5 DISCUSSION
Identifying biomarkers in time course metabolic data
and inferring significant associations with heteroge-
neous omic variables is extremely challenging due to
the several sources of variations of the data. In addi-
tion, existing methods developed to analyze such data
are very scarce and have the limitations of i) overfitting
to the few available data points or ii) confounding the
experimental and longitudinal variation or iii) ignor-
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Figure 7: Posterior distributions of φe for each path-
way for each treatment group. Posterior distributions
of φe are very similar for both controls and cases which
is indicative of no -or mild- pathway alterations.
ing the metabolite interactions or iv) ignoring effects
of other omic variables. In this paper, the model we
have developed combines several approaches to take
into account the different aspects of the data namely
the number of time points, the experimental variation
captured by µit, interactions between metabolites cap-
tured by φ and interactions with additional omic vari-
ables captured by βm.
Our results demonstrate that our model success-
fully addresses the main questions of a metabolomic
study. Most importantly, our model is able to iden-
tify metabolic biomarkers related to treatment, infer
perturbed pathways as a result of treatment and find
significant associations with additional omic variables.
We have shown that providing an informative prior
on metabolic pathways and an informative prior over
the parameter φ is a significant improvement over the
DPPCA model. Particularly, our model is more ro-
bust to slight variations usually observed in short time
series data thanks to the small number of covariance
parameters needed to estimate compared to DPPCA.
We have also shown through simulation that an in-
formative beta like prior compares better than a non-
informative uniform prior in inferring significant path-
ways. On real data, we have investigated how the num-
ber of profiled metabolites can affect the predictive
ability of the model.
Several potential extensions arise naturally from our
model. In terms of the metabolite interactions com-
ponent, many research questions can arise. Alter-
native strategies to modeling metabolite interactions
can be examined such as modeling the non-zero el-
ements of the adjacency matrix C of each pathway
as random variables. This strategy was adopted in
the CAR literature by [16, 24] to take into account
step changes in spatial variation. Step changes can
potentially be useful to model changes in metabolites
correlations as a result of treatment. [15] provide an
overview of different CAR models used in spatial mod-
eling. The proposed models can be adapted to fit into
the metabolomics literature.
From a practical point of view, the model has been
fitted using HMC sampling but takes a large amount
of time (about 1 hour) mostly because of the variable
selection procedure and metabolites interdependence.
This could be addressed by using variational Bayes. In
fact, variational Bayes inference procedures offer cost-
effective inference by means of principled approxima-
tions and appealing computational time for high di-
mensional data. A variational bayes inference of CAR
models was proposed by [12] for high dimensional data,
and a variational bayes approach for variable selection
was recently proposed by [20].
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Figure 8: Estimates of effects of bacteria on metabolite
profiles are captured by βm.
6 CONCLUSION
Metabolomics longitudinal profiling techniques are im-
perative to understand the effect of a drug or a disease
across time and can provide enhanced understanding
of the underlying biology of the system. In a data in-
tegration framework, we have illustrated the use of
the CAR model to incorporate metabolites interac-
tions in the model and the horseshoe prior to iden-
tify association with heterogeneous omic variables ob-
tained by other omic techniques. The combination of
the CAR and horseshoe levels yields the “integrative
CAR Horseshoe” (iCARH) model which we presented
in this article.
Although, it is computationally expensive, the iCARH
model has various appealing features such that it is
able to identify metabolic biomarkers related to treat-
ment, infer perturbed pathways as a result of treat-
ment and identify potential associations between het-
erogeneous omic variables. Clearly, these appealing
features open up further research topics.
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